ProfileGDS5678 / 1427763_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 80% 79% 83% 78% 82% 78% 80% 79% 79% 82% 78% 79% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.6625980
GSM967853U87-EV human glioblastoma xenograft - Control 25.7147580
GSM967854U87-EV human glioblastoma xenograft - Control 35.589679
GSM967855U87-EV human glioblastoma xenograft - Control 46.178583
GSM967856U87-EV human glioblastoma xenograft - Control 55.4171878
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7382582
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2774778
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.647880
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5291179
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5489679
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9557282
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4085878
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5300279
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5884880